Skip to Main Content
New Patients:
564 2270
purple human egg cell under microscope


EmbryoGlue® is an embryo culture medium enriched with a substance called hyaluronan used in the final step of IVF treatment.

How is EmbyroGlue® used in treatment?

There are no known risks from the use of EmbryoGlue® but, based on our experience, we don’t place hatched blastocysts (embryos which have emerged or are emerging from their outer shell) before transfer into EmbryoGlue.

The independent regulator of fertility treatment, the Human Fertilisation and Embryology Authority (HFEA), has developed a ‘red-amber-green’ rating system and provides information on their website about treatments that are offered on top of your routine fertility treatment – known as treatment add-ons. They consider that the only way to be confident that a treatment is effective enough to be used routinely is to carry out a randomised controlled trial (RCT). In an RCT, patients are assigned randomly to two groups: a treatment group, given the new treatment and a control group, given a well-tried treatment or a placebo.

The HFEA has given EmbryoGlue® an amber rating because there is only one high quality study which shows that the use of hyaluronan enriched medium improves live birth rates: other studies are only of moderate quality and further high-quality studies are needed to prove the effectiveness of the treatment. CARE’s own experience of EmbryoGlue® is that it does not have a proven benefit. The HFEA raises no concerns about the safety of EmbryoGlue®

We believe it is important that you have all the information you need before you decide to have treatment using EmbryoGlue®. We also recommend that you read the information on the HFEA website before making a decision

EmbryoGlue® on the HFEA website